Job Family: Clinical Research
Employment Type: Part-time
Duration: 12 months renewable with a 3-month probationary period
Location: ANRS-MIE / CREMER-IMPM, Yaoundé
I. Introduction
National Agency for Research on AIDS, Viral Hepatitis and Emerging Infectious Diseases (ANRS-MIE)
The ANRS | MIE Cameroon site was established on January 25, 2005, following a tripartite memorandum of understanding, renewed on December 16, 2021, between ANRS, the Ministry of Public Health, and the Ministry of Scientific Research and Innovation. Located within the Yaoundé Central Hospital, the site brings together researchers from the Global North and South, from all disciplines and affiliations, to address scientific questions identified as priorities. The site’s mission is to facilitate, evaluate, coordinate, and monitor research projects on HIV/AIDS, viral hepatitis, STIs, tuberculosis, and emerging infectious diseases sponsored or funded by ANRS-MIE. It is under the joint responsibility of a Northern Coordinator and a Southern Coordinator.
Center for Research on Emerging and Re-Emerging Diseases (CREMER)
, officially established in 2009, is one of the four Research Centers of the IMPM. Its mission focuses on research into emerging and re-emerging infectious diseases of immediate or potential importance to public health at the national or international level. Within the framework of its mission and under the authority of a CREMER Director, the Center develops and coordinates research activities on its own initiative or in collaboration with international partners, such as the IRD, with which a collaboration agreement has existed for many years. It is within this collaborative context that one of the IRD’s most important partnership tools, the LMI (International Joint Laboratory), has existed for nearly 10 years between the TransVIHMI research unit based in Montpellier and the CREMER.
As part of the implementation of the ELDORADO project, it is necessary to recruit a full-time Clinical Study Physician who will be responsible for the daily management of project participants.
2
II. Job Description
a)
Context
Dolutegravir treatment has been associated with weight gain, particularly in women and individuals of sub-Saharan African descent (NAMSAL and ADVANCE trials). The long-term detrimental impact of increased weight gain on cardiovascular risk, hypertension, and diabetes is a cause for concern. Conversely, doravirine has been associated with moderate weight gain comparable to that observed with other non-INSTI drugs. Efavirenz 400 mg is currently recommended by the WHO as a possible alternative to dolutegravir, but very high rates of primary resistance mutations in countries where nevirapine and efavirenz have been used for more than 20 years hinder its widespread use. In a context where no first-line studies are currently underway comparing doravirine to dolutegravir, a first-line study evaluating the non-inferiority of doravirine and its superior safety profile compared to dolutegravir in an ethnically diverse population is likely to have a significant public health impact. Indeed, according to WHO guidelines, dolutegravir remains the preferred first-line treatment regimen for people living with HIV initiating ART. If non-inferiority is confirmed, doravirine could be a preferred option in certain populations to avoid adverse events related to metabolic changes caused by the INSTI-based regimen.
b)
Primary objective of the study
: To evaluate the non-inferiority of doravirine in combination with tenofovir and lamivudine, compared to dolutegravir in combination with tenofovir and lamivudine or emtricitabine, in terms of virological efficacy at week 48, measured by the proportion of subjects achieving an HIV-1 RNA < 50 copies/mL, in treatment-naïve HIV-1-infected subjects with a pre-treatment viral load (HIV-1 RNA) ≥ 1000 copies/mL.
c)
Study location:
The Cameroonian research team will be based at the ANRS site and at CREMER in Yaoundé. Patients will be recruited and followed up at the Yaoundé Central Hospital.
d)
Mission:
Reporting to the principal investigators, the mission is to assist them in ensuring that the study is conducted in accordance with the protocol, national and international regulations, and good clinical practice. This includes, among other things, the following activities:
➢
Recruitment of study participants
•
Verifying the eligibility criteria for all participants
.
Provide explanations about the study through the information sheet and obtain informed consent from all eligible participants/legal guardians in the study.
•
Clinically and physically assess all potential study participants during the pre-inclusion period.
•
Review and interpret laboratory results for biochemistry, hematology, serology, microbiology, as well as clinical examination results such as chest X-rays, EEG, etc.
•
Formally recruit eligible and consenting study participants after assessment during the pre-inclusion period.
•
Randomize participants into study arms according to the computerized procedure described in the protocol.
•
Prescribe study medications and ensure adherence by the enrolled participant according to the protocol specifications.
3
➢
Supervision of the generation and recording of quality data at the trial site
•
Complete informed consent forms accurately, fully, and on time according to GCP.
•
Complete all sections of the case report form legibly and accurately.
•
Verify that the data recorded in the case report form is consistent with the source data.
•
Supervise the treatment and follow-up of participants according to the follow-up schedule and during unscheduled visits.
➢
Adverse Event Notification, Monitoring, and Management
•
Supervise nursing care provided to patients, identify and record adverse events.
•
Report and follow up in a timely manner on all serious adverse events that may occur during the study period, as well as cases of pregnancy as defined in the protocol.
•
Assess the severity of adverse events by classifying them using standard tables, and determine causality in the case of (serious) adverse events, according to the protocol.
➢
Coordinate adherence to the trial protocol at the study site by supervising trial-related activities
•
Ensure that all study documents are up-to-date and accurate.
•
Ensure the processing of national and international requests.
•
Ensure, coordinate, organize and optimize the flow of medical equipment and inventory management.
III. Required Qualifications
Skills
• Documented experience in the management of HIV/AIDS cases.
• Clinical research skills highly desirable.
• Excellent communication and interpersonal skills.
• Organized and self-motivated.
• Essential computer skills (MS Word, Excel, PowerPoint, editor).
• Application of Good Clinical Practice (GCP).
➢ Education
• General medical training is essential (MD, MBBS, MBChB medicine).
• Public health training is an asset
. • Current training in Good Clinical Practice (GCP).
➢ Skills
• Meticulous, organized, and self-motivated
. • Maintains confidentiality of sensitive information and strong professional ethics.
• Ability to work under pressure.
• Flexible, tenacious, calm, and teachable.
Applications, consisting of a CV, a cover letter addressed to the Scientific and Technical Co-Coordinator of CREMER, and copies of diplomas, must be sent by email to mabougt27@gmail.com, with copies to charleskouanfack@yahoo.fr and mfeukeuliliane@yahoo.com, no later than June 20, 2026, at 3:00 PM.
ANRS-MIE and CREMER, through their recruitment policies, promote gender equality in the workplace. Only shortlisted candidates will be contacted for an interview.
